A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma

Summary: Cisplatin is a cornerstone chemotherapy for nasopharyngeal carcinoma (NPC); however, certain patients are ineligible for cisplatin-based regimens. This phase 2 trial (NCT04405622) evaluated the efficacy and safety of gemcitabine and toripalimab in previously untreated patients with recurren...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xiong Zou, Xi Ding, Zheng-Kai Feng, Yan-Feng Ouyang, Hui-Feng Li, Kai Wen, Zhi-Qiang Wang, You-Ping Liu, Yong-Long Liu, Wei-Jing Zhang, Qi Yang, Si-Yuan Chen, Yu-Long Xie, Ruo-Qi Xie, Chao Lin, Chen-Mei Gu, Pei-Yu Huang, Rui Sun, Yi-Jun Hua, Rui You, Ming-Yuan Chen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-10-01
coleção:	Cell Reports Medicine
Assuntos:	nasopharyngeal carcinoma cisplatin gemcitabine PD-1 ineligible first-line
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2666379124005263
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!